A Study of Vinflunine Plus Gemcitabine Versus Paclitaxel Plus Gemcitabine in Patients With Advanced Breast Cancer
Status:
Terminated
Trial end date:
2015-02-01
Target enrollment:
Participant gender:
Summary
The combination of vinflunine and gemcitabine in advanced breast cancer in comparison to
paclitaxel and gemcitabine is based on the following points: the significant antitumour
activity of vinflunine in metastatic breast cancer (MBC) as single agent after
anthracycline-taxane exposure and recent phase I study results of the vinflunine plus
gemcitabine is at least additive and both drugs have a distinct mechanism of action; since
taxanes have been approved in the adjuvant setting and are widely used in the treatment of
early breast cancer it is worthwhile to assess new combination chemotherapy regimens as first
line therapy for metastatic breast cancer.